These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 34249371)

  • 41. Exploring conceptual and theoretical frameworks for nurse practitioner education: a scoping review protocol.
    Wilson R; Godfrey CM; Sears K; Medves J; Ross-White A; Lambert N
    JBI Database System Rev Implement Rep; 2015 Oct; 13(10):146-55. PubMed ID: 26571290
    [TBL] [Abstract][Full Text] [Related]  

  • 42. What is the value of routinely testing full blood count, electrolytes and urea, and pulmonary function tests before elective surgery in patients with no apparent clinical indication and in subgroups of patients with common comorbidities: a systematic review of the clinical and cost-effective literature.
    Czoski-Murray C; Lloyd Jones M; McCabe C; Claxton K; Oluboyede Y; Roberts J; Nicholl JP; Rees A; Reilly CS; Young D; Fleming T
    Health Technol Assess; 2012 Dec; 16(50):i-xvi, 1-159. PubMed ID: 23302507
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Consultation on changes to technology appraisals.
    Nurs Manag (Harrow); 2016 Dec; 23(8):11. PubMed ID: 27905247
    [TBL] [Abstract][Full Text] [Related]  

  • 44. How should cost-effectiveness analysis be used in health technology coverage decisions? Evidence from the National Institute for Health and Clinical Excellence approach.
    Williams I; Bryan S; McIver S
    J Health Serv Res Policy; 2007 Apr; 12(2):73-9. PubMed ID: 17407655
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Parent-delivered interventions used at home to improve eating, drinking and swallowing in children with neurodisability: the FEEDS mixed-methods study.
    Parr J; Pennington L; Taylor H; Craig D; Morris C; McConachie H; Cadwgan J; Sellers D; Andrew M; Smith J; Garland D; McColl E; Buswell C; Thomas J; Colver A
    Health Technol Assess; 2021 Mar; 25(22):1-208. PubMed ID: 33769272
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The cancer technology appraisal programme of the UK's National Institute for Clinical Excellence.
    Littlejohns P; Barnett D; Longson C;
    Lancet Oncol; 2003 Apr; 4(4):242-50. PubMed ID: 12681268
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The eClinical Care Pathway Framework: a novel structure for creation of online complex clinical care pathways and its application in the management of sexually transmitted infections.
    Gibbs J; Sutcliffe LJ; Gkatzidou V; Hone K; Ashcroft RE; Harding-Esch EM; Lowndes CM; Sadiq ST; Sonnenberg P; Estcourt CS
    BMC Med Inform Decis Mak; 2016 Jul; 16():98. PubMed ID: 27448797
    [TBL] [Abstract][Full Text] [Related]  

  • 48. National Institute for Health and Care Excellence clinical guidelines development principles and processes.
    Garbi M
    Heart; 2021 May; 107(12):949-953. PubMed ID: 33622678
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Modifying NICE's Approach to Equity Weighting.
    Paulden M; McCabe C
    Pharmacoeconomics; 2021 Feb; 39(2):147-160. PubMed ID: 33517512
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An analysis of NICE's 'restricted' (or 'optimized') decisions.
    O'Neill P; Devlin NJ
    Pharmacoeconomics; 2010; 28(11):987-93. PubMed ID: 20936882
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Health economic evaluation in England.
    Raftery J
    Z Evid Fortbild Qual Gesundhwes; 2014; 108(7):367-74. PubMed ID: 25444294
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The impact of the National Institute for Health Research Health Technology Assessment programme, 2003-13: a multimethod evaluation.
    Guthrie S; Bienkowska-Gibbs T; Manville C; Pollitt A; Kirtley A; Wooding S
    Health Technol Assess; 2015 Aug; 19(67):1-291. PubMed ID: 26307643
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Review of the role of NICE in promoting the adoption of innovative cardiac technologies.
    Groves PH; Pomfrett C; Marlow M
    Heart; 2018 Nov; 104(22):1817-1822. PubMed ID: 29773657
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Some inconsistencies in NICE's consideration of social values.
    Paulden M; O'Mahony JF; Culyer AJ; McCabe C
    Pharmacoeconomics; 2014 Nov; 32(11):1043-53. PubMed ID: 25145802
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Using health outcomes data to inform decision-making: government agency perspective.
    Taylor R
    Pharmacoeconomics; 2001; 19 Suppl 2():33-8. PubMed ID: 11700787
    [TBL] [Abstract][Full Text] [Related]  

  • 56. An assessment of the impact of the NHS Health Technology Assessment Programme.
    Hanney S; Buxton M; Green C; Coulson D; Raftery J
    Health Technol Assess; 2007 Dec; 11(53):iii-iv, ix-xi, 1-180. PubMed ID: 18031652
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A NICE perspective on computable biomedical knowledge.
    Mitchell A
    BMJ Health Care Inform; 2020 Jul; 27(2):. PubMed ID: 32723854
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A comparison of HAS & NICE guidelines for the economic evaluation of health technologies in the context of their respective national health care systems and cultural environments.
    Massetti M; Aballéa S; Videau Y; Rémuzat C; Roïz J; Toumi M
    J Mark Access Health Policy; 2015; 3():. PubMed ID: 27123190
    [TBL] [Abstract][Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.